Image used for representative purposes only.
| Photo Credit: Arrangement
Hyderabad-based vaccine maker Biological E. will produce Chinese biopharmaceutical firm Jiangsu Recbio Technology Company’s recombinant 9-valent HPV (HPV9) vaccine REC603 under a licensing cooperation agreement the companies announced on Monday.
The Hong Kong stock exchange listed Recbio, under the agreement, will provide BE with drug substance (DS) and transfer technology to formulate, fill and package the vaccines. Technology transfer for the DS production will be given at an appropriate time in future, the companies said in a release.
BE will receive exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. It will begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed.
The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal and oropharyngeal cancers as well as genital warts.
Following the license agreement, Recbio has started transferring necessary technical knowledge, materials and expertise to BE for producing the vaccine. It will continue to support BE in clinical development and regulatory approvals. Their collaboration comes at a time when the global demand for cervical cancer prevention is at an all-time high. By leveraging BE’s advanced manufacturing capabilities, their partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets, the companies said.
“This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India and jointly make greater contributions to global public health,” Founder, Chairman and CEO of Recbio Liu Yong said.
The Chinese firm has a portfolio of at least 10 high-value innovative vaccines covering major disease areas such as cervical cancer, herpes zoster and respiratory syncytial virus. REC603, one of its core products, is for people aged 9-45 years and currently in the phase III clinical trials in China.
BE Managing Director Mahima Datla the company and Recbio are committed to ensure the life-saving vaccine is delivered to those who need it the most.
Published – June 30, 2025 09:32 PM is
